



Contacts: Tularik Inc.
Andrew J. Perlman, M.D., Ph.D.
650-825-7000

Burns McClellan
Juling Chao (Media)
415-352-6262
John Nugent (Investors)
212-213-0006

For Immediate Release

Tularik Names Juan Jaen, Ph.D., Vice President, Chemistry

South San Francisco, CA – June 16, 2000 – Tularik Inc. (NASDAQ: TLRK) today announced that it has named Juan C. Jaen, Ph.D. to the newly created position of Vice President, Chemistry. Dr. Jaen, who has been with Tularik since 1996, previously held the title of Director, Medicinal Chemistry.

“This promotion recognizes Juan’s leadership in building an outstanding and productive chemistry department at Tularik and the seminal role that he has played in moving the Company’s leads into preclinical and clinical development,” said Terry Rosen, Ph.D., Vice President, Research Operations. “Juan’s exceptional commitment and drive have greatly influenced the progression of all of Tularik’s lead development programs and helped to integrate medicinal chemistry as a central component of Tularik’s drug discovery process.”

Prior to joining Tularik in 1996, Dr. Jaen, 42, was Director of Medicinal Chemistry for the Parke-Davis Pharmaceutical Research Division of Warner-Lambert. During this time, he managed the neurodegenerative diseases research area focusing primarily on Alzheimer’s disease drugs and anti-neuroinflammation agents for multiple sclerosis, Alzheimer’s and stroke. Dr. Jaen has authored over 50 peer-reviewed scientific publications and is an inventor on over 30 issued U.S. patents on medicinal agents. Dr. Jaen received his Ph.D. in Organic Chemistry from the University of Michigan in 1983.

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, lipid disorders and bacterial diseases, and a class of targets known as orphan nuclear receptors. Tularik has established strategic partnerships with Japan Tobacco Inc., Roche Bioscience and Knoll AG. For additional information, visit Tularik’s Internet website at www.tularik.com

-more-

Statements in this press release that are not strictly historical are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. There can be no assurance that Tularik will obtain necessary regulatory approvals for its drug candidates or be able to develop a commercially viable pharmaceutical product. These and other risks are more fully discussed in Tularik’s SEC reports, including the report on Form 10-Q for the quarter ended March 31, 2000.

###